Some pharmacies also produce 2.5 mg/mL formulations
The correct classification: Pure GLP-1 agonists: exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, efpeglenatide, orforglipron Dual GIP/GLP-1 agonists: tirzepatide Triple agonists (GIP/GLP-1/glucagon): retatrutide Retatrutide, approved in early 2026, adds glucagon receptor agonism to the dual GIP/GLP-1 mechanism
Vitamin and mineral supplements for the primary prevention of cardiovascular disease and cancer: updated evidence report and systematic review for the US Preventive Services Task Force
GLP1 Drugs (Wegovy, Zepbound): Pros: Highly effective, non-invasive, strong appetite suppression, rapid results